---
title: "Projected preventable pneumococcal disease in Japanese adults ≥65: PCV21 versus PCV20"
id: "medrxiv-15-estimation-of-preventable-pneumococcal-disease-burden-by-pcv20-or-pcv21-under"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-estimation-of-preventable-pneumococcal-disease-burden-by-pcv20-or-pcv21-under"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.15.26363097v1?rss=1"
published_at: "2026-09-16T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Projected preventable pneumococcal disease in Japanese adults ≥65: PCV21 versus PCV20
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-estimation-of-preventable-pneumococcal-disease-burden-by-pcv20-or-pcv21-under
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.15.26363097v1?rss=1)
- **Published At:** 2026-09-16T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Aim: estimate the number of invasive pneumococcal disease (**IPD**) and pneumococcal community-acquired pneumonia (**pCAP**) cases preventable among Japanese adults aged ≥65 years if PCV20 or PCV21 are used in the national immunization program. - Data sources: nationwide adult IPD surveillance and a multicenter pCAP study; serotype distribution among isolates and annual IPD incidence were monitored. - Pandemic effect: mean annual IPD incidence in adults ≥65 years fell during COVID-19 and recovered to 89% of the pre-pandemic level by 2025. - Serotype distribution: during 2023–2025, **PCV20-non-PCV21** serotypes comprised 8.5% of isolates in adults ≥65 years. - Vaccine coverage: modelling assumed the current vaccination coverage of 40% among the target population. - Preventable cases (at 40% coverage): estimated preventable IPD cases per person per year were 36 with **PCV20** and 53 with **PCV21**; estimated preventable pCAP cases were 2,821 (PCV20) and 4,765 (PCV21). - Relative impact: PCV21 could prevent approximately 1.5–1.7 times more pneumococcal disease cases than PCV20 in adults ≥65 years in Japan. - Burden comparison: estimated preventable pCAP cases were roughly 80–90 times higher than preventable IPD cases. - Policy caveat: authors note PCV20 should be considered if incidence of IPD caused by PCV20-non-PCV21 serotypes increases. - Ethics and availability: study approved by relevant ethics committees; data available upon reasonable request.
## Clinical Analysis & Structured Key Points
Estimation of preventable pneumococcal disease burden by PCV20 or PCV21 under the national immunization program for adults aged 65 years in Japan | medRxiv Skip to main content Estimation of preventable pneumococcal disease burden by PCV20 or PCV21 under the national immunization program for adults aged 65 years in Japan Kosuke Tamura , Bin Chang , Reiko Shimbashi , Kenji Gotoh , Yoshinari Tanabe , Koji Kuronuma , Kengo Ohshima , Takaya Maruyama , Msashi Nakamatsu , Shuichi Abe , Kei Kasahara , Tadasuke Ooka , Yu Arakawa , Yuki Kinjo , Yukihiro Akeda , Kazunori Oishi doi: https://doi.org/10.64898/2026.09.15.26363097 Kosuke Tamura 1 Department of Research Planning, Toyama Institute of Health, Toyama, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bin Chang 2 Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Reiko Shimbashi 3 Department of Infectious Disease Surveillance, National Institute of Infectious Diseases, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kenji Gotoh 4 Department of Infection Control and Prevention, Kurume University School of Medicine, Fukuoka, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yoshinari Tanabe 5 Department of Respiratory Medicine, Niigata Prefectural Shibata Hospital, Niigata, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Koji Kuronuma 6 Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Hokkaido, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kengo Ohshima 7 Department of Infectious Disease, Tohoku University Graduate School of Medicine, Miyagi, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Takaya Maruyama 8 Mie Prefectural Ichishi Hospital, Mie, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Msashi Nakamatsu 9 Department of Infectious, Respiratory and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Shuichi Abe 10 Department of Infection Control and Prevention, Yamagata Prefectural Central Hospital, Yamagata, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kei Kasahara 11 Center for Infectious Diseases, Nara Medical University, Nara, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tadasuke Ooka 12 Department of Microbiology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yu Arakawa 13 Department of Clinical Infectious Diseases, Kochi Medical School, Kochi University, Kochi, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yuki Kinjo 14 Department of Bacteriology, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yukihiro Akeda 2 Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kazunori Oishi 15 Toyama Institute of Health Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: toyamaeiken1{at}chic.ocn.ne.jp Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Aims: To estimate the preventable pneumococcal disease burden by 21-valent pneumococcal conjugate vaccine (PCV21) compared to PCV20 for the national immunization program for adults aged 65 years or older in Japan. Methods: Serotype distribution among isolates and the annual incidence of invasive pneumococcal disease (IPD) in adults were monitored. The numbers of IPD or pneumococcal community-acquired pneumonia (pCAP) cases preventable by immunization with PCV20 or PCV21 were estimated according to reported vaccine efficacy and duration of protection in older adults. Data from our nationwide study of adult IPD surveillance and a multicenter study of pCAP were used. Results: The mean annual incidence of adult patients with IPD caused by all serotypes among adults aged ≥65 years, which declined during the COVID-19 pandemic period, recovered to 89% of the pre-pandemic level in 2025. During 2023–2025, the proportion of PCV20-non-PCV21 serotypes was 8.5% for adults aged ≥65 years. At the current vaccination coverage rate of 40%, the numbers of preventable IPD cases (per person per year) by PCV20 and PCV21 were 36 and 53, respectively. The preventable numbers of pCAP cases by PCV20 and PCV21 were 2,821 and 4,765, respectively. The estimated number of preventable pCAP cases was approximately 80–90 times higher than that of preventable IPD cases. Conclusion: Our data indicate that PCV21 could prevent 1.5–1.7 times as many pneumococcal disease cases as PCV20 among adults aged ≥ 65 years in Japan. However, PCV20 should be considered if the incidence of adult IPD cases caused by PCV20-non-PCV21 serotypes increases. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was reviewed and approved by the Medical Research Ethics Committee of JIHS, NIID (approval no. 707) and conducted in accordance with the tenets of the Declaration of Helsinki. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data will be made available upon reasonable request. Funder Information Declared the Ministry of Health, Labor and Welfare Humanitarian Assistance Program , JPMH25HA1001 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 16, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Estimation of preventable pneumococcal disease burden by PCV20 or PCV21 under the national immunization program for adults aged 65 years in Japan Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Estimation of preventable pneumococcal disease burden by PCV20 or PCV21 under the national immunization program for adults aged 65 years in Japan Kosuke Tamura , Bin Chang , Reiko Shimbashi , Kenji Gotoh , Yoshinari Tanabe , Koji Kuronuma , Kengo Ohshima , Takaya Maruyama , Msashi Nakamatsu , Shuichi Abe , Kei Kasahara , Tadasuke Ooka , Yu Arakawa , Yuki Kinjo , Yukihiro Akeda , Kazunori Oishi medRxiv 2026.09.15.26363097; doi: https://doi.org/10.64898/2026.09.15.26363097 Share This Article: Copy Citation Tools Estimation of preventable pneumococcal disease burden by PCV20 or PCV21 under the national immunization program for adults aged 65 years in Japan Kosuke Tamura , Bin Chang , Reiko Shimbashi , Kenji Gotoh , Yoshinari Tanabe , Koji Kuronuma , Kengo Ohshima , Takaya Maruyama , Msashi Nakamatsu , Shuichi Abe , Kei Kasahara , Tadasuke Ooka , Yu Arakawa , Yuki Kinjo , Yukihiro Akeda , Kazunori Oishi medRxiv 2026.09.15.26363097; doi: https://doi.org/10.64898/2026.09.15.26363097 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (902) Anesthesia (333) Cardiovascular Medicine (4819) Dentistry and Oral Medicine (479) Dermatology (415) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1629) Epidemiology (15953) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7050) Geriatric Medicine (733) Health Economics (1065) Health Informatics (5051) Health Policy (1435) Health Systems and Quality Improvement (1768) Hematology (585) HIV/AIDS (1344) Infectious Diseases (except HIV/AIDS) (16295) Intensive Care and Critical Care Medicine (1173) Medical Education (668) Medical Ethics (155) Nephrology (724) Neurology (7276) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1241) Occupational and Environmental Health (1005) Oncology (3610) Ophthalmology (1053) Orthopedics (398) Otolaryngology (457) Pain Medicine (470) Palliative Medicine (139) Pathology (709) Pediatrics (1799) Pharmacology and Therapeutics (737) Primary Care Research (767) Psychiatry and Clinical Psychology (5902) Public and Global Health (9761) Radiology and Imaging (2425) Rehabilitation Medicine and Physical Therapy (1453) Respiratory Medicine (1249) Rheumatology (641) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [Kennedy renews attacks on vaccines at Children’s Health Defense conference](https://medichelpline.com/clinical-feed/stat-news-1-kennedy-renews-attacks-on-vaccines-at-children-s-health-defense-conference.md)
- [Study says purer fentanyl won’t by itself explain U.S. overdose death decline](https://medichelpline.com/clinical-feed/stat-news-2-purer-fentanyl-won-t-solve-the-u-s-overdose-death-crisis-study-says.md)
- [Cost-Effectiveness of Ensitrelvir Post-Exposure Prophylaxis for High-Risk Household Contacts in Ja](https://medichelpline.com/clinical-feed/medrxiv-0-cost-effectiveness-of-ensitrelvir-for-covid-19-post-exposure-prophylaxis-among.md)
- [Disentangling Immune Waning and Viral Evolution on COVID-19 Booster Effectiveness](https://medichelpline.com/clinical-feed/medrxiv-22-separating-the-effects-of-immune-waning-and-viral-evolution-on-covid-19-vaccine.md)
- [Retinal changes on OCT may predict atrial fibrillation risk years before diagnosis](https://medichelpline.com/clinical-feed/medical-news-today-0-how-changes-in-the-eyes-may-help-spot-afib-risk-years-early.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.